For a female patient with invasive ductal carcinoma grade 2 (estrogen‑receptor low positive, progesterone‑receptor negative, HER2‑negative, Ki‑67 40%) who completed neoadjuvant doxorubicin‑cyclophosphamide plus toripalimab, paclitaxel‑carboplatin plus toripalimab, surgery (ypT0N0), adjuvant radiotherapy and one year of toripalimab, is now on anastrozole and has mild back pain with imaging showing multiple spinal bone metastases, what is the next step in management?

Management of New-Onset Spinal Metastases in ER-Low Positive, HER2-Negative Breast Cancer After Complete Response to Neoadjuvant Therapy

This patient requires immediate initiation of a bone-modifying agent (denosumab 120 mg subcutaneously or zoledronic acid 4 mg IV every 3-4 weeks), continuation of anastrozole, and consideration of switching to a CDK4/6 inhibitor plus aromatase inhibitor combination given the ER-low status and high Ki-67 (40%) indicating aggressive biology.

Immediate Priorities

1. Bone-Modifying Agent Initiation

The presence of multiple spinal metastases on MRI mandates immediate bone-targeted therapy. Start denosumab 120 mg subcutaneously every 4 weeks OR zoledronic acid 4 mg IV over at least 15 minutes every 3-4 weeks 1, 2. These agents reduce skeletal-related events (pathologic fractures, spinal cord compression, need for radiation or surgery) and provide modest pain control 1, 3.

• Denosumab or zoledronic acid have equivalent efficacy for preventing skeletal complications 1
• Continue bone-modifying therapy indefinitely while the patient maintains reasonable performance status 1, 3
• Monitor renal function before each dose; adjust dosing per FDA guidelines if creatinine clearance declines 1
• Ensure calcium and vitamin D supplementation (1000 mg calcium, 800 IU vitamin D3 daily) to prevent hypocalcemia 4
• Maintain good dental hygiene and complete any necessary dental work before starting therapy to minimize osteonecrosis of the jaw risk 5

2. Assess for Spinal Instability and Neurological Compromise

Urgent evaluation is critical given the multifocal vertebral involvement (S1, L1, L3, L4, L5, D10, D11, D12, spinous processes) 2, 5:

• Calculate the Spinal Instability Neoplastic Score (SINS) for each affected level 5
• Perform detailed neurological examination focusing on motor strength, sensation, reflexes, and sphincter function
• If SINS ≥7 or any neurological deficits present, obtain immediate orthopedic/neurosurgical consultation 2, 5
• The mild back pain without movement restriction is reassuring, but close monitoring is essential

3. Systemic Therapy Modification

Critical Context: ER-Low Status

This patient's ER 4/8 (low positive 1%-10%) represents a challenging biology 2, 6:

• ER-low tumors behave more like triple-negative disease with poor endocrine responsiveness 2
• The high Ki-67 (40%) and rapid recurrence (within months of completing adjuvant therapy) confirm aggressive biology
• However, any ER positivity warrants endocrine-based therapy as first-line treatment for bone-only metastatic disease 2, 6

Recommended Systemic Approach

Switch from anastrozole monotherapy to CDK4/6 inhibitor plus aromatase inhibitor combination 6:

• Palbociclib 125 mg daily (21 days on/7 days off) + anastrozole 1 mg daily OR
• Ribociclib 600 mg daily (21 days on/7 days off) + anastrozole 1 mg daily OR
• Abemaciclib 150 mg twice daily continuously + anastrozole 1 mg daily

Rationale: CDK4/6 inhibitors significantly improve progression-free survival in ER-positive/HER2-negative metastatic breast cancer, including ER-low tumors 2, 6. Given the aggressive biology (high Ki-67, rapid recurrence, ER-low status), single-agent endocrine therapy is insufficient.

Alternative Consideration: Chemotherapy

If visceral crisis develops or rapid progression occurs on CDK4/6 inhibitor therapy, chemotherapy becomes the preferred option 2, 7:

• Taxanes (paclitaxel, docetaxel) are reasonable given prior anthracycline exposure
• Capecitabine is an alternative oral option
• Note: The patient already received AC and paclitaxel-carboplatin in the neoadjuvant setting

4. Radiation Therapy Consideration

Palliative radiation to symptomatic spinal sites should be considered if pain worsens or neurological symptoms develop 2, 5:

• Conventional external beam radiation (single 8 Gy fraction or fractionated 20-30 Gy) for pain control
• Stereotactic body radiotherapy (SBRT) may be considered for oligometastatic disease with longer life expectancy 5
• Radiation provides effective pain relief within 1-2 weeks 2

Monitoring Strategy

Imaging Surveillance

• Repeat MRI spine in 2-3 months to assess response to systemic therapy and bone-modifying agents 2
• PET-CT every 3-4 months to monitor for extraskeletal disease progression 6
• Earlier imaging if new symptoms develop (neurological changes, severe pain, functional decline)

Laboratory Monitoring

• Complete blood count, comprehensive metabolic panel (including calcium, creatinine) every 3-4 weeks initially, then per CDK4/6 inhibitor protocol
• Bone turnover markers (optional) may help assess bone-modifying agent response 4

Clinical Assessment

• Monthly clinical evaluation for performance status, pain control, neurological function
• SINS reassessment if new back pain or imaging changes occur 5

Critical Pitfalls to Avoid

1. Do NOT delay bone-modifying agent initiation – skeletal complications occur rapidly and significantly impact quality of life 1, 3

2. Do NOT rely on anastrozole monotherapy – ER-low status with high Ki-67 requires intensified endocrine therapy (CDK4/6 inhibitor combination) 2, 6

3. Do NOT miss spinal cord compression – maintain low threshold for urgent MRI if neurological symptoms develop; this is an oncologic emergency requiring immediate intervention 2

4. Do NOT assume residual microcalcifications indicate viable disease – the patient achieved ypT0N0, representing true pathologic complete response 2

5. Do NOT overlook dental evaluation – complete dental work before starting bone-modifying agents to minimize osteonecrosis risk 5

6. Do NOT stop bone-modifying therapy prematurely – continue indefinitely while performance status remains reasonable 1, 3

Prognosis Discussion

Despite bone metastases, this patient has several favorable prognostic features:

• Bone-only disease (no visceral metastases) 2, 7
• Excellent response to prior therapy (ypT0N0) suggests chemosensitive biology
• Good performance status (mild pain, no functional limitation)
• Postmenopausal status allows full endocrine therapy options

Median survival for bone-only ER-positive metastatic breast cancer exceeds 3-5 years with modern therapy 2, 6. The ER-low status and high Ki-67 temper this optimism somewhat, but aggressive multimodal management offers meaningful disease control and quality of life.